Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Shares of Moderna Inc (NASDAQ: MRNA) were up premarket after the UK approved its COVID-19 vaccine for use in the country that imposed a lockdown earlier this week in efforts to control the rising coronavirus cases.
The biotech company said that it appreciates the confidence shown by the UK MHRA in its COVID-19 vaccine, which is an important step in the global fight against the virus that had become a global pandemic.
Moderna’s vaccine is composed of two doses administered 28 days apart and is approved for people aged 18 year and older. The vaccine has an efficacy rate of 94% and could help reverse the growing coronavirus cases in the UK.
The UK first approved the Pfizer/BionTech vaccine on December two followed by Oxford University/AstraZeneca vaccine on December 30, making Moderna’s vaccine the last to receive approval in the country.
Moderna’s vaccine has so far received approval from the European Union, the US, Israel and Canada, but its stock price has been falling ever since early December 2020 despite the recent approvals.
It is not yet clear whether Moderna’s vaccine is effective against the two virulent strains of the COVID-19 vaccine that were discovered in South Africa and the UK.
Pfizer and BionTech today said that in vitro studies have shown that its vaccine effectively neutralizes the mutated variants of the SARS-CoV-2 virus discovered in the two countries above.
Moderna share price
Moderna shares were up 1.82% premarket to trade at $117.23 having slightly higher from Thursday’s closing price of $115.09.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .